Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Jennifer Russo

Brain Injury Medicine Saddle Brook, NJ Medical Doctor

NPI 1740635044 CMS profile 9628008

300 Market St, Saddle Brook, NJ 07663

Open in the dashboard

General payments

$482

29 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Russo of Saddle Brook, NJ is reported in the CMS Open Payments database as having received $482 across 29 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $160 9
2024 General $170 11
2023 General $125 7
2022 General $27 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Russo
  • Brain Injury Medicine median
  • Middle half of Brain Injury Medicine
  • National median

In program year 2025, general payments to Jennifer Russo were reported at $160. Among 31 Brain Injury Medicine profiles paid that year, the median was $165 and the middle half received between $36 and $391.

Show as a table
Year Jennifer Russo Brain Injury Medicine median Middle half National median
2019 $0 $110 $51–$240 $163
2020 $0 — — $114
2021 $0 $61 $22–$274 $132
2022 $27 $79 $26–$281 $149
2023 $125 $125 $49–$275 $160
2024 $170 $139 $75–$423 $164
2025 $160 $165 $36–$391 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Ipsen Biopharmaceuticals, Inc $157 9 payments
  2. AbbVie, Inc. $150 10 payments
  3. UCB, Inc. $60 3 payments
  4. Merz Pharmaceuticals, LLC $56 3 payments
  5. Otsuka America Pharmaceutical, Inc. $28 2 payments
  6. Microtransponder, Inc. $16 1 payment
  7. Allergan Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $482 29 payments
Products named General payments · program years 2022–2025
  1. DYSPORT $157 9 payments
  2. BOTOX Botox Therapeutic $137 9 payments
  3. Briviact $60 3 payments
  4. Xeomin $56 3 payments
  5. NUEDEXTA $28 2 payments
  6. BOTOX Hyperhydrosis $27 2 payments
  7. QULIPTA $18 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

721

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$65,478

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

16.1%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 58 $38,078
Jardiance Empagliflozin Brand 15 $14,248
Brilinta Ticagrelor Brand 15 $7,286
Atorvastatin Calcium Generic 89 $705
Levetiracetam Generic 14 $447
Pantoprazole Sodium Generic 47 $417
Tamsulosin Hcl Generic 32 $402
Gabapentin Generic 37 $322
Metoprolol Succinate Generic 28 $322
Baclofen Generic 16 $320

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$226,245

Of which drugs: $56,032

Medicare patients

259

Average age 79

Services billed

13,702

137 women, 122 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Ischemic heart disease 58%
Heart failure 48%
Diabetes 46%
Atrial fibrillation 41%
Depression 40%
Chronic kidney disease 36%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 12 7,800 $38,815

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $91
$91 — 7,800
DYSPORT
  • Ipsen Biopharmaceuticals, Inc $58
$58 — —
Briviact
  • UCB, Inc. $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

29 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Brain Injury Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record